June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Sub-Tenon’s capsule 0.1% adrenaline versus placebo in maintenance of mydriasis during vitrectomy.
Author Affiliations & Notes
  • Thais Andrade
    Universidade de São Paulo, Sao Paulo, Brazil
  • Rafael B Barbosa de Araujo
    Universidade de São Paulo, Sao Paulo, Brazil
  • Gabriela de Sousa Martins Melo
    Federal University of Rio Grande do Norte, Natal, Brazil
  • Breno Marques da Silva Azevedo
    Universidade de São Paulo, Sao Paulo, Brazil
  • Pedro C Carricondo
    Universidade de São Paulo, Sao Paulo, Brazil
  • Footnotes
    Commercial Relationships   Thais Andrade, None; Rafael Barbosa de Araujo, None; Gabriela Melo, None; Breno Azevedo, None; Pedro Carricondo, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2800. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Thais Andrade, Rafael B Barbosa de Araujo, Gabriela de Sousa Martins Melo, Breno Marques da Silva Azevedo, Pedro C Carricondo; Sub-Tenon’s capsule 0.1% adrenaline versus placebo in maintenance of mydriasis during vitrectomy.
      . Invest. Ophthalmol. Vis. Sci. 2017;58(8):2800.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Adequate mydriasis is important during vitrectomy surgery to facilitate vitreous removal and membrane peeling. On the other hand, poor pupil dilation may lead to complications as accidental retinal tears, lens and retinal touching, and non-intentional reminiscent of cortical vitreous, both on the posterior pole and vitreous base. We designed this randomized, double-blinded trial to determine whether the use of sub-Tenon’s capsule injection of 0.2 cc 0.1% adrenaline improves the maintenance of mydriasis during vitrectomy, in comparison with placebo.

Methods : Thirty-four eyes (34 patients) submitted to primary vitrectomy were enrolled. Informed consent was taken in all cases. All patients were preoperatively dilated with 3 drops of 0,5% tropicamide 30 minutes before procedure. They were then randomly assigned in one of two groups: adrenaline (treatment group) or saline (placebo group). In group adrenaline, 0.2 cc of 0.1% adrenaline was injected in the inferior perilimbic area, with a 27-gauge needle, under the Tenon’s capsule, immediatelly before beginning of the surgery; in group saline, 0.2 cc of Balanced Saline Solution (BSS) was injected following the same techique, as a placebo. Pupil horizontal diameter was measured with a milimetric scale prior to the initial injection and immediately after surgery, through microscope visualization. Gender, age, phakic status, duration of surgery, history of diabetes and possible complications were also recorded.

Results : Mean preoperative pupil diameter was 6.68 mm [standard deviation (SD):1.09] in the adrenaline group and 6.5 mm (SD: 1.03) in the placebo group, with no significant difference. Postoperative measurements were 7.29 mm (SD: 0.63) in the adrenaline group and 6.17 mm (SD: 0.88) in placebo group, and this difference was significant larger (p<0.001). There was no difference between groups regarding gender, age, surgery duration, diagnosis of diabetes or phakic status. No surgical or clinical complications were reported.

Conclusions : Sub-Tenon’s capsule adrenaline immediately before surgery was effective in maintaining mydriasis during vitrectomy. Despite the absence of complications, this procedure appears safe and may assist especially in more difficult surgical scenarios. More studies should be performed for better conclusions about other clinical outcomes.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.